GlaxoSmithKline PLC ADR (GSK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlaxoSmithKline PLC ADR (GSK) has a cash flow conversion efficiency ratio of 0.149x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.54 Billion) by net assets ($17.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GlaxoSmithKline PLC ADR market capitalisation for the company's overall valuation and market capitalisation.
GlaxoSmithKline PLC ADR - Cash Flow Conversion Efficiency Trend (1990–2025)
This chart illustrates how GlaxoSmithKline PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GlaxoSmithKline PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlaxoSmithKline PLC ADR ranked by their cash flow conversion efficiency. Explore GSK cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Shenhua Energy Co
SHG:601088
|
0.054x |
|
PDD Holdings Inc.
NASDAQ:PDD
|
0.110x |
|
UNICREDIT S.P.A. ADR
F:CRIP
|
N/A |
|
ServiceNow Inc
NYSE:NOW
|
0.173x |
|
FAST RETAIL. CO. ADR 1/10
F:FR70
|
0.073x |
|
Hon Hai Precision Industry Co Ltd
TW:2317
|
0.141x |
|
Equinor ASA
OL:EQNR
|
0.494x |
|
DBS GROUP ADR/4 SD 1
F:DEV
|
N/A |
Annual Cash Flow Conversion Efficiency for GlaxoSmithKline PLC ADR (1990–2025)
The table below shows the annual cash flow conversion efficiency of GlaxoSmithKline PLC ADR from 1990 to 2025. View GSK live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.99 Billion | $7.14 Billion | 0.447x | -10.83% |
| 2024-12-31 | $13.09 Billion | $6.55 Billion | 0.501x | +3.53% |
| 2023-12-31 | $16.31 Billion | $7.89 Billion | 0.484x | -34.02% |
| 2022-12-31 | $10.10 Billion | $7.40 Billion | 0.733x | +166.55% |
| 2021-12-31 | $28.91 Billion | $7.95 Billion | 0.275x | -7.30% |
| 2020-12-31 | $28.44 Billion | $8.44 Billion | 0.297x | -10.01% |
| 2019-12-31 | $24.32 Billion | $8.02 Billion | 0.330x | -85.62% |
| 2018-12-31 | $3.67 Billion | $8.42 Billion | 2.293x | +15.66% |
| 2017-12-31 | $3.49 Billion | $6.92 Billion | 1.983x | +51.46% |
| 2016-12-31 | $4.96 Billion | $6.50 Billion | 1.309x | +352.40% |
| 2015-12-31 | $8.88 Billion | $2.57 Billion | 0.289x | -72.41% |
| 2014-12-31 | $4.94 Billion | $5.18 Billion | 1.049x | +13.43% |
| 2013-12-31 | $7.81 Billion | $7.22 Billion | 0.924x | +42.57% |
| 2012-12-31 | $6.75 Billion | $4.38 Billion | 0.648x | -8.42% |
| 2011-12-31 | $8.83 Billion | $6.25 Billion | 0.708x | +1.52% |
| 2010-12-31 | $9.74 Billion | $6.80 Billion | 0.697x | -4.45% |
| 2009-12-31 | $10.74 Billion | $7.84 Billion | 0.730x | -16.95% |
| 2008-12-31 | $8.32 Billion | $7.31 Billion | 0.879x | +41.24% |
| 2007-12-31 | $9.91 Billion | $6.17 Billion | 0.622x | +47.22% |
| 2006-12-31 | $9.65 Billion | $4.08 Billion | 0.423x | -48.37% |
| 2005-12-31 | $7.57 Billion | $6.20 Billion | 0.819x | -1.65% |
| 2004-12-31 | $5.94 Billion | $4.94 Billion | 0.832x | +45.05% |
| 2003-12-31 | $8.45 Billion | $4.85 Billion | 0.574x | +38.56% |
| 2002-12-31 | $7.39 Billion | $3.06 Billion | 0.414x | -24.54% |
| 2001-12-31 | $8.40 Billion | $4.61 Billion | 0.549x | +165.41% |
| 2000-12-31 | $8.96 Billion | $1.85 Billion | 0.207x | +29.48% |
| 1999-12-31 | $3.19 Billion | $510.00 Million | 0.160x | +7.83% |
| 1998-12-31 | $2.77 Billion | $410.00 Million | 0.148x | -54.48% |
| 1997-12-31 | $1.89 Billion | $615.00 Million | 0.325x | -51.44% |
| 1996-12-31 | $1.27 Billion | $849.00 Million | 0.670x | -88.17% |
| 1995-12-31 | $221.00 Million | $1.25 Billion | 5.665x | +32.94% |
| 1994-12-31 | $574.69 Million | $2.45 Billion | 4.261x | +1983.79% |
| 1993-12-31 | $5.15 Billion | $1.05 Billion | 0.205x | +2.74% |
| 1992-12-31 | $4.66 Billion | $927.00 Million | 0.199x | +10.25% |
| 1991-12-31 | $3.64 Billion | $657.00 Million | 0.181x | -3.65% |
| 1990-12-31 | $3.28 Billion | $615.00 Million | 0.187x | -- |
About GlaxoSmithKline PLC ADR
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more